Interleukin (IL)-23 inhibitors, which are mainly used for psoriasis, are making their way into the field of palmoplantar pustulosis in Korea.

Following the approval of Janssen Korea’s ‘Tremfya (guselkumab), AbbVie Korea’s Skyrizi (risankizumab) has also added an indication for palmoplantar pustulosis and has signaled competition in the area.

In the case of Tremfya, its reimbursement standard was extended to cover palmoplantar pustulosis as well. Currently, Tremfya is reimbursed for: ▲patients with a PPPASI score of 12 or higher, who have been treated with acitretin or methotrexate or cyclosporine at therapeutic doses for at least 3 months but are unable to continue treatment due to n